drugset / Trial / NCT05600114
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).
Timeline
- Start
- 2022-10-27
- Primary completion
- 2023-12-13
- Completion
- 2023-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 150 mg | Oral |
| Subject | Cannabidiol | Other / unclassified | 300 mg | Oral |